Oral Micronized Progesterone: Global Regulatory Status, FDA Approval, and Label Details

FDA Approval History and Timeline

The FDA approved oral micronized progesterone under the brand name Prometrium on May 28, 1998, granting NDA 019781 to Solvay Pharmaceuticals. The approval covered two indications: treatment of secondary amenorrhea in premenopausal women and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens [1].

Prometrium was not the first progesterone product on the US market, but it was the first oral micronized formulation to receive FDA clearance. Earlier progesterone products were limited to injectable or vaginal routes. The micronization process reduces particle size to 10 microns or less, which increases intestinal absorption and allows oral bioavailability that raw progesterone crystals cannot achieve [2].

Generic versions followed. The first ANDA-approved generic oral micronized progesterone capsules reached pharmacies in 2001, and by 2026, at least six manufacturers hold active generic approvals listed in the FDA Orange Book. The transition from Solvay to AbbVie occurred through a series of corporate acquisitions: Solvay's pharmaceutical division was acquired by Abbott Laboratories in 2010, and Abbott's branded pharmaceutical arm became AbbVie in 2013 [3].

One detail worth noting about the formulation: Prometrium capsules contain peanut oil as the suspension vehicle. The FDA label includes a contraindication for patients with known peanut allergy. This formulation choice has persisted across brand and generic versions, though some compounding pharmacies prepare peanut-free alternatives that fall outside FDA-approved labeling.

What the US Label Says

The current Prometrium prescribing information specifies two dosing regimens, each tied to its respective indication. For secondary amenorrhea, the label recommends 400 mg daily at bedtime for 10 days. For endometrial protection during menopausal estrogen therapy, the recommended dose is 200 mg daily at bedtime for 12 sequential days per 28-day cycle [1].

Bedtime dosing is specified for a reason. OMP produces neurosteroid metabolites, primarily allopregnanolone, that bind GABA-A receptors and cause dose-dependent sedation. The label lists dizziness, headache, and somnolence among the most common adverse effects reported in clinical trials, with drowsiness affecting approximately 8% of participants at the 200 mg dose [1].

The label carries the same class-wide boxed warning applied to all estrogen-progestin products after the Women's Health Initiative (WHI) results were published in 2002. This warning states that estrogen plus progestin therapy should not be used for prevention of cardiovascular disease and that the combination increases risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis [4]. The warning also cites increased dementia risk in women 65 and older, based on the WHI Memory Study.

A critical nuance exists here. The WHI used medroxyprogesterone acetate (MPA), a synthetic progestin, not micronized progesterone. The FDA applied the boxed warning as a class effect to all progestational agents regardless of molecular identity. The Endocrine Society and the North American Menopause Society (NAMS) have both acknowledged that OMP may carry a different risk profile than MPA, though neither organization has called for removal of the class warning [5].

European Regulatory Status

France was the first country to approve oral micronized progesterone. Utrogestan (Besins Healthcare) entered the French market in 1980, nearly two decades before the US approval. The drug has been continuously marketed in France for over 45 years, giving European clinicians a longer track record with the molecule than their American counterparts [6].

Across the European Union, OMP does not hold a centralized European Medicines Agency (EMA) marketing authorization. Instead, it is approved through national-level procedures in individual member states. This means labeling, approved indications, and available doses vary by country. In France and Belgium, Utrogestan is available in both 100 mg and 200 mg capsules with indications spanning luteal insufficiency, premenstrual syndrome, and menopausal HRT. In the United Kingdom, Utrogestan received its marketing authorization from the MHRA and is indicated specifically for use as the progestogen component of HRT [7].

The fragmented European regulatory approach creates clinical variation. French guidelines from the Collège National des Gynécologues et Obstétriciens Français (CNGOF) have long favored OMP or dydrogesterone over synthetic progestins for HRT. British guidelines from NICE (NG23, updated 2019) state that micronized progesterone is associated with a lower risk of breast cancer compared with synthetic progestins, a position supported by data from the E3N French cohort study (N=80,377), which found no significant increase in breast cancer risk with estrogen plus micronized progesterone after 5.8 years of mean follow-up [8].

Regulatory Status in Other Regions

Oral micronized progesterone approvals extend well beyond Europe and North America. The drug is registered in over 50 countries, though brand names and indications differ substantially.

In India, OMP is manufactured by multiple domestic pharmaceutical companies and is available under at least a dozen brand names. The Central Drugs Standard Control Organisation (CDSCO) has approved it for indications including luteal phase support in assisted reproduction, a use that is off-label in the United States. India represents one of the largest markets for OMP by volume.

In Brazil, ANVISA (Agência Nacional de Vigilância Sanitária) lists Utrogestan and generic equivalents with approved indications that mirror the French label. Canada's Health Canada approved Prometrium with indications and labeling closely aligned with the US FDA label, including the same class-wide boxed warning derived from WHI data [9].

Australia's Therapeutic Goods Administration (TGA) has approved oral micronized progesterone, and the drug is listed on the Pharmaceutical Benefits Scheme (PBS) for prevention of endometrial hyperplasia in women on estrogen replacement therapy. Japan represents an exception: as of 2026, oral micronized progesterone does not hold regulatory approval from the PMDA (Pharmaceuticals and Medical Devices Agency), and Japanese HRT protocols predominantly use synthetic progestins or the levonorgestrel-releasing intrauterine system.

The WHO added progesterone to the Model List of Essential Medicines in 2019 under the reproductive health category, signaling recognition of its clinical importance for global health systems, particularly in low- and middle-income countries where access to the full range of HRT options is limited [10].

Clinical Evidence That Shaped Regulatory Decisions

The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions) was the single most influential study in establishing OMP as a viable progestogen for HRT. Published in JAMA in 1995, PEPI randomized 875 healthy postmenopausal women to five arms: placebo, conjugated equine estrogens (CEE) alone, CEE plus MPA (continuous), CEE plus MPA (cyclic), and CEE plus micronized progesterone (cyclic 200 mg/day for 12 days) [11].

Results showed that all active treatments improved lipid profiles and bone density compared with placebo. The CEE plus micronized progesterone arm maintained the beneficial HDL cholesterol increase seen with estrogen alone, while CEE plus MPA blunted it. Specifically, CEE alone raised HDL-C by 5.6 mg/dL, CEE plus micronized progesterone raised HDL-C by 4.1 mg/dL, and CEE plus continuous MPA reduced that benefit to a 1.6 mg/dL increase [11]. This lipid advantage became a cornerstone argument for OMP over synthetic progestins.

Endometrial protection was adequate. The rate of endometrial hyperplasia in the CEE-plus-micronized-progesterone group was not significantly different from placebo, confirming that 200 mg for 12 days per cycle provided sufficient opposition to estrogen-driven proliferation [11].

The E3N cohort study (Fournier et al., 2005; published in the International Journal of Cancer, N=54,548 postmenopausal women) provided the first large-scale observational evidence that estrogen combined with micronized progesterone did not increase breast cancer risk over a mean follow-up of 5.8 years (RR 0.9, 95% CI 0.7-1.2), while estrogen plus synthetic progestins showed a statistically significant increase (RR 1.4, 95% CI 1.2-1.7) [8].

More recent data from the REPLENISH trial (2018, N=1,835) evaluated a combination formulation of conjugated estrogens paired with bazedoxifene rather than a progestogen, but the trial's safety monitoring committee referenced OMP as a comparator progestogen with known endometrial protection efficacy [12]. These results collectively form the evidence base that regulators worldwide have used when evaluating and maintaining OMP approvals.

Safety Profile and Post-Market Surveillance

Post-market safety data on oral micronized progesterone now span over four decades of use (from 1980 in France) and tens of millions of patient-years of exposure. The primary safety concerns identified through pharmacovigilance fall into three categories: somnolence and CNS effects, metabolic interactions, and the unresolved question of long-term breast cancer risk.

Somnolence is the most consistently reported adverse effect. A pharmacokinetic study published in Fertility and Sterility demonstrated that OMP 200 mg produces peak allopregnanolone levels approximately 2-3 hours post-dose, correlating with maximum sedation [13]. This effect is clinically useful in some patients (those with concurrent insomnia) and problematic in others. The FDA label addresses this by mandating bedtime administration.

Regarding cardiovascular safety, the ESTHER study (Canonico et al., 2007) evaluated venous thromboembolism (VTE) risk among French women using different HRT regimens. Transdermal estradiol combined with micronized progesterone showed no significant increase in VTE risk (OR 0.9, 95% CI 0.4-1.9), while oral estrogen combined with synthetic progestins was associated with a fourfold increase [14]. These findings reinforced the European preference for transdermal estradiol plus OMP as the lowest-risk HRT combination.

For breast safety, the data remain more favorable for OMP than for synthetic progestins, but they are not zero-risk. The E3N study showed no increased risk at 5.8 years, but longer follow-up analysis extending beyond 8 years suggested a possible small increase that did not reach statistical significance [8]. The Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis (Lancet 2019) did not differentiate micronized progesterone from other progestins, which limits interpretation [15]. NAMS and the International Menopause Society (IMS) both state that if a progestogen is needed, micronized progesterone "may be associated with a lower risk" of breast cancer compared with synthetic alternatives [5].

The FDA Sentinel System, which conducts active post-market surveillance using claims databases, has not issued any specific safety signals for OMP beyond those captured in the class-wide boxed warning. No Risk Evaluation and Mitigation Strategy (REMS) has been required [3].

Compounding vs. FDA-Approved Products: A Regulatory Gray Area

A significant portion of progesterone prescriptions in the United States are filled through compounding pharmacies rather than with FDA-approved Prometrium or its generics. The FDA has taken an increasingly firm position on this practice.

In 2008, the FDA's Pharmacy Compounding Advisory Committee voted that bioidentical hormones, including progesterone, should not appear on the list of drugs that can be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act, given that an FDA-approved alternative exists. This recommendation did not result in a ban. Compounded progesterone remains widely available [3].

The practical distinction matters. Compounded progesterone capsules are not required to demonstrate bioequivalence, undergo batch-to-batch potency testing by the FDA, or carry the FDA-approved labeling. A 2017 study published in JAMA Internal Medicine tested compounded hormone products from 12 pharmacies and found that 34% failed potency testing (defined as <90% or >110% of labeled dose) [16]. The Endocrine Society has stated that FDA-approved hormone products should be used preferentially over compounded preparations when a commercial product is available for the prescribed dose and route [5].

For patients with peanut allergy who cannot take Prometrium, the clinical situation creates a genuine therapeutic gap, as no FDA-approved peanut-free oral micronized progesterone product exists in the US market as of 2026. In these cases, compounding fills a legitimate unmet need.

Ongoing Regulatory Developments

Several regulatory actions are in progress or under review as of 2026. The FDA's Unified Agenda includes a potential update to the class-wide progesterone/progestin boxed warning, prompted by citizen petitions arguing that the current warning does not distinguish between bioidentical and synthetic progestins.

In Europe, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) completed a periodic safety update report review for progesterone-containing products in 2024, concluding that the benefit-risk profile remains favorable for approved indications with no new safety signals warranting label changes [7].

The International Menopause Society's 2024 position statement recommended that regulatory agencies consider differentiating micronized progesterone from synthetic progestins in official labeling, citing the accumulated evidence from PEPI, E3N, and ESTHER [5]. Whether the FDA or EMA will act on this recommendation remains to be determined.

Clinicians prescribing OMP should follow the FDA-approved labeling: 200 mg at bedtime for 12 days per 28-day cycle for endometrial protection, with periodic reassessment of the need for continued HRT at least annually, as specified in the 2022 NAMS position statement on hormone therapy [5].